Effects of Novel E-cigarette Constituents on Adults TCORS 3.0

NCT05932745 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-12-26

No results posted yet for this study

Summary

This study is an examination of the influence of cooling components of WS-3, WS-23, and menthol on the appeal and addiction potential of nicotine-containing e-liquids among adults.

Conditions

  • Nicotine Use Disorder

Interventions

OTHER

E-liquid coolant (No WS-3) for non-menthol (1)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.

OTHER

E-liquid coolant (No WS-3) for low (0.1%) menthol (1)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.

OTHER

E-liquid coolant (No WS-3) for high (2.0%) menthol (1)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.

OTHER

E-liquid coolant (Low [0.1%] WS-3) for non-menthol (2)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.

OTHER

E-liquid coolant (Low [0.1%] WS-3) for low (0.1%) menthol (2)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.

OTHER

E-liquid coolant (Low [0.1%] WS-3) for high (2.0%) menthol (2)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.

OTHER

E-liquid coolant (High [2.0%] WS-3) for non-menthol (3)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.

OTHER

E-liquid coolant (High [2.0%] WS-3) for low (0.1%) menthol (3)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.

OTHER

E-liquid coolant (High [2.0%] WS-3) for high (2.0%) menthol (3)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.

OTHER

E-liquid coolant (Low [0.1%] WS-23) for non-menthol (4)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.

OTHER

E-liquid coolant (Low [0.1%] WS-23) for low (0.1%) menthol (4)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.

OTHER

E-liquid coolant (Low [0.1%] WS-23) for high (2.0%) menthol (4)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.

OTHER

E-liquid coolant (High [2.0%] WS-23) for non-menthol (5)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.

OTHER

E-liquid coolant (High [2.0%] WS-23) for low (0.1%) menthol (5)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.

OTHER

E-liquid coolant (High [2.0%] WS-23) for high (2.0%) menthol (5)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.

OTHER

E-liquid coolant (4% WS-23) for non-menthol (6)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with 4% WS-23 concentration.

OTHER

E-liquid coolant (4% WS-23) for low (0.1%) menthol (6)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with 4% WS-23 concentration.

OTHER

E-liquid coolant (4% WS-23) for high (2.0%) menthol (6)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with 4% WS-23 concentration.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH
  • Yale University

    lead OTHER

Principal Investigators

  • Suchitra Krishnan-Sarin, PhD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-20
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05932745 on ClinicalTrials.gov